Renaissance Technologies LLC Has $5.10 Million Stake in LifeStance Health Group, Inc. $LFST

Key Points

• Renaissance Technologies increased its LifeStance Health Group stake by 92.5% in the first quarter, owning 800,500 shares worth approximately $5.1 million. Institutional investors collectively hold 85.5% of LFST.
• LifeStance delivered strong second-quarter results: Revenue rose 26.1% year over year to $435.4 million and adjusted earnings reached $0.06 per share, beating estimates. The company also raised its 2026 outlook and authorized a new $100 million share-repurchase program.
• Analyst sentiment is moderately bullish, but insider selling is notable: LFST has an average “Moderate Buy” rating and an $11.50 price target, while insiders sold 7.6 million shares worth about $62.9 million over the past three months.

Renaissance Technologies LLC lifted its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 92.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 800,500 shares of the company's stock after purchasing an additional 384,600 shares during the quarter. Renaissance Technologies LLC owned 0.21% of LifeStance Health Group worth $5,099,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Larson Financial Group LLC increased its stake in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company's stock valued at $27,000 after buying an additional 3,791 shares during the period. KBC Group NV purchased a new stake in LifeStance Health Group in the 1st quarter worth approximately $29,000. PNC Financial Services Group Inc. boosted its stake in shares of LifeStance Health Group by 615.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock valued at $59,000 after buying an additional 7,987 shares during the period. Assetmark Inc. boosted its stake in shares of LifeStance Health Group by 17.0% during the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company's stock valued at $60,000 after buying an additional 1,367 shares during the period. Finally, Bayesian Capital Management LP purchased a new position in shares of LifeStance Health Group during the 2nd quarter valued at $52,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

More LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates: LifeStance reported adjusted earnings of $0.06 per share versus the $0.03 consensus estimate. Revenue rose 26% year over year to $435.4 million, above expectations of approximately $414.6 million. LifeStance Health Group Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved sharply: The company swung to $23.6 million of net income from a $3.8 million loss a year earlier. Adjusted EBITDA nearly doubled to $66.0 million, or 15.2% of revenue, helped by higher revenue per visit, lower center costs and operating leverage. LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
• Positive Sentiment: Growth metrics remained strong: Visit volume increased 19% to 2.6 million, while the clinician base expanded 11% to 8,542. Management said growth reflected clinician additions, better productivity and increased revenue per visit.
• Positive Sentiment: Full-year outlook was raised: LifeStance now expects 2026 revenue of $1.685 billion to $1.725 billion, Center Margin of $570 million to $594 million and adjusted EBITDA of $215 million to $235 million. Third-quarter revenue guidance of $420 million to $440 million also exceeds the prior consensus of roughly $417.7 million. The board additionally authorized a new $100 million share-repurchase program.
• Neutral Sentiment: Cash generation was a strength, but leverage remains relevant: Operating cash flow reached $99.9 million in Q2 and cash totaled $225.9 million at quarter-end, compared with $259.0 million of net long-term debt. The balance sheet supports continued investment and buybacks, although debt exceeds cash.
• Negative Sentiment: Investors should monitor execution risks: LifeStance remains exposed to clinician recruitment and retention, reimbursement pressure, healthcare regulation and competition. Reported insider activity also shows substantial selling by certain holders, which could create supply pressure even though it does not directly change operating performance.

Insiders Place Their Bets

In other LifeStance Health Group news, Director Robert Bessler sold 894,337 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the transaction, the director directly owned 539,763 shares of the company's stock, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Darren M. Black sold 5,899,661 shares of the firm's stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $47,315,281.22. Following the transaction, the director owned 23,310,115 shares in the company, valued at approximately $186,947,122.30. This trade represents a 20.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,612,394 shares of company stock valued at $62,938,451 over the last three months. 3.50% of the stock is currently owned by insiders.

LifeStance Health Group Stock Performance

LFST stock opened at $10.66 on Friday. The firm has a 50 day moving average of $9.88 and a two-hundred day moving average of $8.03. LifeStance Health Group, Inc. has a 12 month low of $3.81 and a 12 month high of $11.76. The company has a market capitalization of $4.13 billion, a price-to-earnings ratio of 177.67 and a beta of 1.14. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The business had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. During the same quarter last year, the firm earned ($0.01) EPS. LifeStance Health Group's revenue for the quarter was up 26.1% on a year-over-year basis. As a group, equities analysts anticipate that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LFST. The Goldman Sachs Group started coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They issued a "neutral" rating and a $9.00 price target on the stock. BTIG Research lifted their price objective on LifeStance Health Group from $12.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, July 24th. Wall Street Zen downgraded LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 25th. JPMorgan Chase & Co. upped their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a "neutral" rating in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group raised their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $11.50.

LifeStance Health Group Company Profile

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

Want to see what other hedge funds are holding LFST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source